<?xml version="1.0" encoding="UTF-8"?>
<p>Identifying new biomarkers that would allow for a quick, inexpensive, and reliable prediction of treatment response and metastatic recurrence of TNBC patients is still an important unsatisfied medical need. Such biomarkers would allow oncologists to propose alternative treatment and enrolment into clinical trials to the TNBC patients carrying a high risk of resistance to the classical NACT or/and a high risk of metastatic recurrence.</p>
